Can a newer drug prevent spine fractures in acromegaly patients?
NCT ID NCT07179926
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study looks at whether the drug Pasireotide LAR can reduce the risk of spine fractures in people with acromegaly better than another drug, Pegvisomant. Acromegaly is a condition where too much growth hormone weakens bones, leading to painful fractures. Researchers will follow 120 patients for one year, comparing those on Pasireotide LAR to past data from patients on Pegvisomant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pasireotide LAR (a drug that lowers growth hormone and IGF-1 levels)
What this could lead to
If successful, this could show that Pasireotide LAR is better at preventing spine fractures in people with acromegaly than the current alternative, Pegvisomant.
What could go wrong
This is a relatively small, non-randomized study comparing a new group to past data, so results may not be definitive. The benefit may be modest or not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACROMEGALY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS UOC Endocrinologia e Diabetologia
RECRUITINGRome, RM, 00168, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact